The autoimmune disease diagnosis market is expected to reach USD 4.73 billion by 2022 from USD 3.09 billion in 2017, at a CAGR of 8.9%. Factors driving the growth of this market include the rising incidence of autoimmune diseases, growing healthcare expenditure, and technological advancements in the diagnosis process.
The autoimmune disease diagnosis market is consolidated in nature due to the presence of a large number of players. The key players in the market are Thermo Fisher Scientific (US), Danaher (US), HYCOR Biomedical (US), Siemens (Germany), Bio-Rad (US), Inova Diagnostics (US), Trinity Biotech (Ireland), Grifols (Spain), and Abbott (US).
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=174826519
The key strategies followed by most companies in the autoimmune disease diagnosis market are product launches and partnerships. These strategies accounted for the largest share of the overall growth strategies mapped from 2015 to 2017. Some of the leading players who adopted this strategy include Siemens (Germany), Bio-Rad (US), Danaher (US), and Abbott (US).
In 2016, Siemens accounted for the largest share of the autoimmune disease diagnosis market. The company has a wide range of products, covering all major technologies in autoimmune disease diagnosis. The company focuses on growing organically by leveraging its high operating margin. In June 2016, Thermo Fisher Scientific introduced new instruments and assays in order to expand the use of clinical testing, enhance laboratory productivity, and improve patient outcomes.
In 2016, Danaher Corporation accounted for the second-largest market share of the autoimmune disease diagnosis market. The company has a broad product portfolio and has launched innovative products to enable the rapid and accurate diagnosis of autoimmune disease. The company primarily focuses on developing technologically advanced diagnostic products for the diagnosis of rheumatoid arthritis to strengthen its position in this market. In 2014, Danaher (Beckman Coulter) and Cytojene Corporation (US) acquired Xitogen Technologies (China) wherein, Xitogen will provide Beckman Coulter with a research instrument to round out their cytometry offering. This strengthened Beckman Coulter’s position in the Chinese market.
